January 8, 2018What's New
Target Health begins the New Year with new clinical programs in psychiatry, neurology and diabetes, and more to come. Our regulatory group now represents over 55 companies at FDA with a pre-IND meeting in neurology planned for next month. Biostatistics is completing an analysis of a major Phase 3 program, in addition to analyses in oncology, urology and other multiple indications. Data management continues to support multiple Target e*CRF® programs, including an ongoing major phase 3 program in Alzheimer's disease. Application development continues to build EDC studies including a new study starting soon in Hong Kong which will use Target e*CTR® (eSource; eClinical Trial Record), as well as a new study just started in diabetes which is using both Target e*ICF™ (eInformed Consent) and Target e*CTR®. Finally, software development continues on the cutting edge with the next version of Target e*Studio®. This user-friendly version will be transformational for the industry as the entire clinical trial will be at one website, there will be full integration with mobile devices and there will be a sophisticated user management schema. Of course, this is just the tip of the iceberg.
For more information about Target Health contact Warren Pearlson (212-681-2100 ext. 165). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel. The Target Health software tools are designed to partner with both CROs and Sponsors.
Joyce Hays, Founder and Editor in Chief of On Target
Jules Mitchel, Editor